Chronic inhibition of dipeptidyl peptidase-IV with ASP8497 improved the HbA1c level, glucose intolerance, and lipid parameter level in streptozotocin-nicotinamide-induced diabetic mice

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 379, Issue 2, 2009, Pages 191-199

  Matsuyama Yokono, Akiko ^a   Tahara, Atsuo ^a   Nakano, Ryosuke ^a   Someya, Yuka ^a   Hayakawa, Masahiko ^a   Shibasaki, Masayuki ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

ASP8497; Diabetes; Dipeptidyl peptidase IV; Glucagon like peptide 1

Indexed keywords

4 FLUORO 1 [[[4 METHYL 1 (METHYLSULFONYL)PIPERIDIN 4 YL]AMINO] ACETYL]PYRROLIDINE 2 CARBONITRILE MONOFUMARATE; ASP 8497; CHOLESTEROL; DIPEPTIDYL PEPTIDASE IV INHIBITOR; FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; NICOTINAMIDE; PHOSPHOENOLPYRUVATE CARBOXYKINASE (GTP); STREPTOZOCIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INHIBITION; FATTY ACID BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; METABOLIC PARAMETERS; MOUSE; NONHUMAN; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DRUG EVALUATION, PRECLINICAL; GLUCOSE INTOLERANCE; HEMOGLOBIN A, GLYCOSYLATED; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIPIDS; MALE; MICE; MICE, INBRED ICR; NIACINAMIDE; PIPERIDINES; PYRROLIDINES; STREPTOZOCIN;

EID: 64949141723     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-008-0348-x     Document Type: Article

References (47)

1. American Diabetes Association 2001 Postprandial blood glucose Diabetes Care 24 775 778
2. American Diabetes Association 2004 Standards of medical care in diabetes Diabetes Care 27 Suppl.1 S15 35
3. K Asplund BE Wiholm F Lithner 1983 Glibenclamide-associated hypoglycaemia: a report on 57 cases Diabetologia 24 412 417
4. R Basu V Chandramouli B Dicke B Landau R Rizza 2005 Obesity and type 2 diabetes impair insulin-induced suppression of glycogenolysis as well as gluconeogenesis Diabetes 54 1942 1948
5. G Boden X Chen P Stein 2001 Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus Am J Physiol Endocrinol Metab 280 E23 E30
6. CF Deacon AH Johnsen JJ Holst 1995 Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo J Clin Endocrinol 80 952 957
7. CF Deacon MA Nauck M Toft-Nielsen L Pridal B Willms JJ Holst 1995 Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects Diabetes 44 1126 1131
8. DJ Drucker 2001 Development of glucagon-like peptide-1 based pharmaceuticals as therapeutic agents for the treatment of diabetes Curr Pharm Des 7 1399 1412
9. DJ Drucker 2007 The role of gut hormones in glucose homeostasis J Clin Invest 117 24 32
10. R Ebert M Nauck W Creutzfeldt 1991 Effect of exogenous or endogenous gastric inhibitory polypeptide (GIP) on plasma triglyceride responses in rats Horm Metab Res 23 517 521
11. L Farilla H Hui C Bertolotto E Kang A Bulotta U Di Mario R Perfetti 2002 Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats Endocrinology 143 4397 4408
12. L Hansen CF Deacon C Orskov JJ Holst 1999 Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine Endocrinology 140 5356 5363
13. AD Harrower 1994 Comparison of efficacy, secondary failure rate, and complications of sulfonylureas J Diabet Complications 8 201 203
14. JJ Holst CF Deacon 1998 Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes Diabetes 47 1663 1670
15. JJ Holst CF Deacon 2004 Glucagon-like-peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus Curr Opin Pharmacol 4 589 596
16. TJ Kieffer CH McIntoch RA Pederson 1995 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV Endocrinology 136 3585 3596
17. C Knauf PD Cani C Perrin MA Iglesias JF Maury E Bernard F Benhamed T Grémeaux DJ Drucker R Kahn J Girard JF Tanti NM Delzenne C Postic R Burcekin 2005 Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage J Clin Invest 115 3554 3563
18. K Kosaka T Kuzuya R Hagura 1994 Insulin secretary response in Japanese type 2 (non-insulin-dependent) diabetic patients Diabetes Res Clin Pract 24 S101 110
19. Li L, Yang G, Li Q, Tan X, Liu H, Tang Y, Boden G (2008) Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab (in press)
20. R Lupi F Dotta L Marselli S Del Guerra M Masini C Santangelo G Patane U Boggi S Piro M Anello E Bergamini F Mosca U Di Mario S Del Prato P Marchetti 2002 Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that b-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated Diabetes 51 1437 1442
21. P Masiello C Broca R Gross M Roye M Manteghetti D Hillaire-Buys 1998 Experimental NIDDM: development of a new model in adult rats administered streptozotocin and nicotinamide Diabetes 47 224 229
22. S Matikainen N Mänttäri A Schweizer A Ulvestad D Mills BE Dunning JE Foley M-R Taskinen 2006 Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes Diabetologia 49 2049 2057
23. A Matsuyama-Yokono A Tahara R Nakano Y Someya I Nagase M Hayakawa M Shibasaki 2008 ASP8497 is a novel selective and competitive dipeptidyl peptidase-IV inhibitor with antihyperglycemic activity Biochem Pharmcol 76 98 107
24. DR Matthews JP Hosker AS Rudenski BA Naylor DF Treacher RC Turner 1985 Homeostasis model assessment: insulin resistance and b-cell function from fasting plasma glucose and insulin concentrations in man Diabetologia 28 412 419
25. JJ Meier MA Nauck 2006 Incretins and the development of type 2 diabetes Curr Diab Rep 6 194 201
26. R Mentlein 1999 Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides Regul Pept 85 9 24
27. M Morifuji K Sakai K Sugiura 2005 Dietary whey protein modulates liver glycogen level and glycoregulatory enzyme activities in exercise-trained rats Exp Biol Med 230 23 30
28. J Mu J Woods YP Zhou RS Roy Z Li E Zycband Y Feng Zhu C Li AD Howard DE Moller NA Thornberry BB Zhang 2006 Chronic inhibition of dipeptidyl peptidase-4 with sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes Diabetes 55 1695 1704
29. RA Pederson HA White D Schlenzig RP Pauly CH McIntoch H-U Deemuth 1998 Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide Diabetes 47 1253 1258
30. KS Polonsky BD Given LJ Hirsch H Tillil ET Shapiro C Beebe BH Frank JA Galloway E Van Cauter 1988 Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus N Engl J Med 318 1231 1239
31. D Porte 1991 b-cells in type II diabetes mellitus Diabetes 40 166 180
32. JA Pospisilik J Martin T Doty JA Ehses N Pamir FC Lynn S Piteau HU Demuth CH McIntoch RA Pederson 2003 Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 52 741 750
33. X Qin H Shen M Liu Q Yang S Zheng M Sabo DA D'Alessio P Tso 2005 GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats Am J Physiol Gastrointest Liver Physiol 288 G943 949
34. I Raz M Hanefeld L Xu C Caria D Williams-Herman H Khatami Sitagliptin Study 023 Group 2006 Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 49 2564 2571
35. MK Reimer JJ Holst B Ahren 2002 Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice Eur J Endocrinol 146 717 727
36. J Rosenstock MA Baron S Dejager D Mills A Schweizer 2007 Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial Diabetes Care 30 217 223
37. Y Someya A Tahara R Nakano A Matsuyama-Yokono I Nagase Y Fukunaga T Takasu M Hayakawa M Shibasaki 2008 Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo Naunyn Schmiedebergs Arch Pharmacol 377 209 217
38. M Stahl W Berger 1999 Higher incidence of severe hypoglycaemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulphonylureas Diabet Med 16 586 590
39. B Sudre P Broqua RB White D Ashworth DM Evans R Haigh ML Junien JL Aubert 2002 Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats Diabetes 51 1461 1469
40. SI Taylor D Accili Y Imai 1994 Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes 43 735 740
41. A Trumper K Trumper H Trusheim R Arnold B Goke D Horsch 2001 Glucose-dependent insulinotropic polypeptide is a growth factor for b (INS-1) cells by pleiotropic signaling Mol Endocrinol 15 1559 1570
42. RH Unger 1995 Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications Diabetes 44 863 870
43. T Wasada K McCorkle H Virginia K Kawai B Howard RH Unger 1981 Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs J Clin Invest 68 1106 1107
44. C Weyer C Bogardu DM Mott RE Pratley 1999 The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 104 787 794
45. AA Young BR Gedulin S Bhavsar N Bodkin C Jodka B Hansen M Denaro 1999 Glucose-Lowering and Insulin-Sensitizing Actions of Exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats and diabetic rhesus monkeys (Macaca mulatta) Diabetes 48 1026 1034
46. YP Zhou VE Grill 1994 Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle J Clin Invest 93 870 876
47. BR Zimmerman 1997 Sulfonylureas Endocrinol Metab Clin North Am 26 511 522